shutterstock_1492661771_ricochet64
ricochet64 / Shutterstock.com
17 March 2020Big PharmaRory O'Neill

Partial win for Mylan as Fed Circuit cancels Boehringer patents

The US Court of Appeals for the Federal Circuit has rescued one Boehringer Ingelheim patent, covering a type 2 diabetes treatment, from invalidation but affirmed a New Jersey district court’s cancellation of two others.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Big Pharma
4 June 2020   In a victory for Mylan, the English High Court has rejected Israel-based pharmaceutical company Neurim’s attempt to delay a generic version of its insomnia medication.
Biotechnology
21 September 2020   The Federal Court of Australia has rejected Boehringer Ingelheim’s animal health unit's attempt to stop the registration of a patent owned by Intervet International on various grounds.
Big Pharma
4 February 2021   Chinese drug maker Qilu’s proposed generic version of a cancer treatment infringes three patents, according to a lawsuit filed by Boehringer Ingelheim.

More on this story

Big Pharma
4 June 2020   In a victory for Mylan, the English High Court has rejected Israel-based pharmaceutical company Neurim’s attempt to delay a generic version of its insomnia medication.
Biotechnology
21 September 2020   The Federal Court of Australia has rejected Boehringer Ingelheim’s animal health unit's attempt to stop the registration of a patent owned by Intervet International on various grounds.
Big Pharma
4 February 2021   Chinese drug maker Qilu’s proposed generic version of a cancer treatment infringes three patents, according to a lawsuit filed by Boehringer Ingelheim.

More on this story

Big Pharma
4 June 2020   In a victory for Mylan, the English High Court has rejected Israel-based pharmaceutical company Neurim’s attempt to delay a generic version of its insomnia medication.
Biotechnology
21 September 2020   The Federal Court of Australia has rejected Boehringer Ingelheim’s animal health unit's attempt to stop the registration of a patent owned by Intervet International on various grounds.
Big Pharma
4 February 2021   Chinese drug maker Qilu’s proposed generic version of a cancer treatment infringes three patents, according to a lawsuit filed by Boehringer Ingelheim.